Amycretin: Novo Nordisk's Next Weight Loss Drug After Wegovy (Phase 3 Update) | Peptadex

What Is Amycretin?

Amycretin is an investigational unimolecular dual agonist developed by Novo Nordisk that combines GLP-1 receptor agonism with amylin receptor agonism in a single molecule. It is designed to mimic and enhance two distinct natural satiety signals — GLP-1, the hormone targeted by semaglutide, and amylin, a pancreatic peptide that complements insulin secretion and signals fullness to the brain.

As of early 2026, Novo Nordisk has initiated Phase 3 clinical trials for amycretin in both obesity and type 2 diabetes, following Phase 2 data that showed 14.5% mean weight loss at 36 weeks in the subcutaneous formulation.

Key Takeaways

• Amycretin is a GLP-1/amylin unimolecular dual agonist — a single drug molecule activating two different satiety receptor systems
• Phase 2 data: 14.5% weight loss at 36 weeks (subcutaneous); A1C reduction up to 1.8% in T2D patients
• Phase 3 initiated in early 2026 for both obesity and type 2 diabetes indications
• Both subcutaneous (injectable) and oral formulations are in development
• No FDA approval expected before 2028 at earliest; NDA filing likely 2027

How Amycretin Is Different From Wegovy and Ozempic

Wegovy and Ozempic are single GLP-1 receptor agonists (semaglutide). Amycretin adds amylin receptor co-activation. Amylin is a hormone co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, reduces post-meal glucagon secretion, and signals satiety through a different brainstem pathway than GLP-1.

The rationale is that combining two complementary satiety mechanisms may produce greater or more sustained weight loss than either mechanism alone — similar to how tirzepatide exceeded semaglutide's weight loss outcomes by adding GIP receptor activation alongside GLP-1.

Amycretin vs. Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is a GIP/GLP-1 dual agonist. Amycretin is a GLP-1/amylin dual agonist. These are different receptor pairings with potentially different clinical profiles. Neither is directly comparable in Phase 3 yet, but head-to-head trials may emerge as both agents progress through development.

Compare these mechanisms side-by-side using our GLP-1 comparison tool.

Phase 2 Data in Detail

Subcutaneous (Injectable) Formulation

The Phase 2 subcutaneous amycretin trial, published at the close of 2025, showed mean weight loss of 14.5% over 36 weeks versus placebo. This is competitive with injectable semaglutide 2.4mg (Wegovy) and somewhat lower than the highest tirzepatide doses, though direct trial comparison is not appropriate due to different populations and study designs.

The A1C reduction of up to 1.8% in type 2 diabetes participants was clinically meaningful, supporting the T2D indication development in Phase 3.

Oral Formulation

Novo Nordisk is also developing an oral amycretin tablet. Phase 2 oral data has shown meaningful but lower weight loss compared to the subcutaneous form — consistent with the general pattern in oral versus injectable GLP-1 delivery. The oral formulation's convenient dosing could provide market differentiation similar to the advantage Foundayo (orforglipron) has over injectable GLP-1s.

Why Amylin Matters

Amylin's natural role in metabolism was established through the study of patients with type 1 and type 2 diabetes, who have deficient amylin secretion alongside insulin deficiency. Pramlintide (Symlin), a synthetic amylin analog, was FDA-approved in 2005 for use in diabetes patients but never achieved wide adoption due to its injection three-times-daily requirement and modest efficacy as a standalone agent.

The key insight driving amycretin is that amylin's satiety effects may be amplified when combined with GLP-1 receptor activation in a single molecule, potentially addressing the limitations pramlintide faced as a standalone agent. Early Phase 2 results support this hypothesis.

Phase 3 Program: What to Watch For

The Phase 3 program initiated in 2026 will need to demonstrate:

• Superior or non-inferior weight loss to approved comparators in large populations (typically 1,500–5,000+ patients)
• Cardiovascular safety data — a regulatory requirement for weight loss drugs
• Acceptable side effect profile at the doses selected for commercialization

Phase 3 trials typically run 18–48 months. Based on a 2026 start, the earliest NDA filing would be around 2027–2028, with FDA approval — assuming positive data — likely no earlier than 2028.

Safety Profile: What Phase 2 Showed

The most commonly reported adverse events in Phase 2 were consistent with GLP-1 class effects: nausea, vomiting, diarrhea, and constipation. Nausea rates were notable in the titration phase. No new safety signals specific to amylin co-activation were highlighted in the published Phase 2 data, though Phase 3 is the appropriate environment to detect lower-frequency safety signals in a larger population.

Where Amycretin Fits in the GLP-1 Landscape

The obesity pharmacotherapy pipeline is evolving rapidly. Approved agents include semaglutide (Wegovy) and tirzepatide (Zepbound) as injectables, plus newly approved oral orforglipron (Foundayo). In Phase 3 is retatrutide, Eli Lilly's triple agonist with NDA filing targeted for Q4 2026. Amycretin enters Phase 3 as another candidate in what is becoming the most active drug development space in modern medicine.

Disclaimer: This article is for educational purposes only. Amycretin is an investigational drug and has not received FDA approval. Nothing in this article constitutes medical advice. All clinical data cited comes from Novo Nordisk investor communications and peer-reviewed publications. Consult a licensed physician for any medical decisions.